CAS |
553-21-9 |
Chinese Name |
木香烃内酯 |
English Name |
Costunolide |
Synonyms |
Costus lactone;(+)-Costunolide;NSC 106404 |
Molecular Formula |
C15H20O2 |
Molecular Weight |
232.32 |
Solubility |
Soluble in DMSO |
Purity |
HPLC≥98% |
Appearance |
White to yellow Solid |
Storage |
Powder:-20℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL |
MFCD00210262 |
SMILES |
O=C(O[C@@]1([H])[C@@]2([H])CC/C(C)=C/CC/C(C)=C/1)C2=C |
InChIKey |
HRYLQFBHBWLLLL-AHNJNIBGSA-N |
InChI |
InChI=1S/C15H20O2/c1-10-5-4-6-11(2)9-14-13(8-7-10)12(3)15(16)17-14/h5,9,13-14H,3-4,6-8H2,1-2H3/b10-5+,11-9+/t13-,14+/m0/s1 |
PubChem CID |
5281437 |
Target Point |
Telomerase;FPTase;Apoptosis |
Passage |
Cell Cycle;DNA Damage/DNA Repair;Metabolic Enzyme&Protease;Apoptosis |
Background |
Costunolide is a sesquiterpene lactone with antioxidant, anti-inflammatory, anti-allergic, bone remodeling, neuroprotective, hair growth promotion, anti-cancer and anti-diabetic activities. Costunolide induces cell cycle arrest and apoptosis in breast cancer. |
Biological Activity |
Costunolide (NSC 106404)是一种天然倍半萜类化合物,具有多种生物活性;抑制FPTase,IC50为20 μM,也抑制telomerase(端粒酶),IC50为65-90 μM。[1] |
In Vitro |
木香烃内酯抑制MCF - 7和MDA - MB - 231端粒酶活性和细胞增殖,该抑制作用呈浓度和时间依赖性[1]。 木香烃内酯也抑制由法尼基蛋白转移酶(FPTase)诱导的人lamin-B法尼基化过程,该抑制效果呈剂量依赖性。木香烃内酯连续处理人肿瘤细胞(A549,SK-OV-3,SK-MEL-2,XF498和HCT-1)48小时,可以剂量依赖的方式降低细胞增殖[2]。木香烃内酯诱导人白血病细胞HL - 60凋亡,可通过活性氧介导的线粒体通透性改变、细胞色素C释放到细胞质引发[3]。最近的一项研究表明,木香烃内酯具有显著的抗真菌活性,包括毛癣菌(Trichophyton mentagrophytes)、猴毛癣菌(T.simlii),红色毛癣菌(T.rubrum)等[4]。 |
In Vivo |
木香烃内酯通过阻断血管生长因子信号转导通路来抑制血管生成。在小鼠角膜微囊模型中,木香烃内酯可降低由VEGF诱导的新生血管形成[5]。 |
Cell Experiment |
1,500 - 10000细胞铺板于96孔板,每孔200μL培养基。余8孔为空白对照。2,细胞在37℃,5% CO2培养箱中培养过夜、贴壁。3,每孔中加入2μL溶解于DMSO的木香烃内酯。置板于振动台,150转5分钟,混匀样品。4,在37℃,5% CO2培养箱中培养48小时使木香烃内酯发生作用。,5,每96孔板加入2 mL或以上MTT溶液,浓度为5毫克/毫升,PBS)。MTT溶液不稳定。现用现配。,6,每孔中加入20μL MTT。振动台上150转5分钟,彻底混合溶液。,7,在37℃,5% CO2培养箱中培养1 - 5小时使细胞代谢。,8,去除培养基。(可用纸巾去除残留)。9,每孔加入200μL DMSO溶解三苯基甲脂(MTT代谢产物)。振动台上150转5分钟,彻底混合溶剂。10,在560nm处读值,减去670nm处背景。[1] |
Data Literature Source |
[1] Choi SH,et al,Cancer Lett,2005,227(2),153-162. [2] Park SH,et al,Planta Med,2001,67(4),358-359. [3] Lee MG,et al,Biol Pharm Bull,2001,24(3),303-306. [4] Duripandiyan V,et al,BMC Complement Altern Med,2012,12,13. [5] Jeong SJ,et al,Cancer Lett,2002,187(1-2),129-133. |
Unit |
Bottle |
Specification |
5mg 10mM*1mL in DMSO 10mg |